How has Anika Therapeutics's gain (loss) on disposition of assets changed year-over-year?

Anika Therapeutics's gain (loss) on disposition of assets decreased by 84.4% year-over-year, from $205K to $32K.

Anika Therapeutics ANIK Gain (Loss) on Disposition of Assets

Globus MedicalGMED

——

AVN

AVNSAVNS

——

Revenue$32.6M+15.6%

Net income$3.3M+183%

EPS (diluted)$0.24—

Cash & equivalents$38.4M-27.8%

Total debt$25.7M+1.2%

Total equity$137.3M-7.0%

Total assets$183.5M-2.2%

Operating cash flow-$684.0K-262%

CapEx$1.4M-1.2%

Free cash flow-$2.1M-28.8%

Market cap$199.85M+23.0%

P/S1.7×-0.1×

Net margin-3.4%-1.6pp

FCF margin0.5%—

Return on equity-2.9%-1.4pp

Debt / equity0.2×0.0×

Current ratio4.5×-1.7×

Reported directly by Anika Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:GainLossOnDispositionOfAssets1.

The official record: Anika Therapeutics’s 8-K, filed July 29, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Anika Therapeutics's gain (loss) on disposition of assets?: Anika Therapeutics (ANIK) reported gain (loss) on disposition of assets of $32K in Q2 2026.
How has Anika Therapeutics's gain (loss) on disposition of assets changed year-over-year?: Anika Therapeutics's gain (loss) on disposition of assets decreased by 84.4% year-over-year, from $205K to $32K.